Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA AND LEVODOPA versus DOPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA AND LEVODOPA versus DOPAR.
CARBIDOPA AND LEVODOPA vs DOPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AADC), thereby replenishing dopamine levels in the striatum. Carbidopa inhibits peripheral AADC, reducing peripheral conversion of levodopa to dopamine, which increases levodopa availability in the brain and decreases peripheral side effects like nausea and vomiting.
DOPAR (levodopa) is a metabolic precursor of dopamine. It crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AADC) in the brain, thereby replenishing striatal dopamine levels and alleviating symptoms of Parkinson's disease.
Initial: 25 mg carbidopa / 100 mg levodopa 3 times daily. Titrate based on response, up to 200 mg carbidopa / 2000 mg levodopa per day in divided doses every 4-6 hours. Immediate-release tablets, oral.
Levodopa 300-600 mg orally 3-4 times daily as Dopar; do not crush or chew extended-release.
None Documented
None Documented
Levodopa (with carbidopa): ~1.5-2 hours (terminal). Carbidopa: ~1-2 hours. Clinical context: Short half-life requires frequent dosing; plasma levodopa fluctuations correlate with motor fluctuations.
Terminal half-life: 1-3 hours (levodopa alone); with carbidopa (Sinemet): 1.5-2 hours due to reduced peripheral metabolism; clinical context: short half-life requires frequent dosing (every 4-6 hours) to maintain therapeutic levels.
Renal: ~70-80% as metabolites (including dopamine, 3-O-methyldopa, homovanillic acid), ~10% as unchanged levodopa; biliary/fecal: <10%. Carbidopa is excreted primarily unchanged in urine (~50%) and as metabolites.
Renal: 70-80% as metabolites (including homovanillic acid, dihydroxyphenylacetic acid, and 3-O-methyldopa); biliary/fecal: ~20% as conjugates and metabolites; unchanged levodopa <1%.
Category A/B
Category C
Dopamine Precursor
Dopamine Precursor